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ABSTRACT
Objective: To develop and validate a multidimensional
generic questionnaire measuring satisfaction with treatment
with medicines. The questionnaire was designed to be used in
chronic patients undergoing pharmacological treatment for
any disease.
Methods: After a literature review and cognitive debrieﬁng
process with an expert panel of six members and 21 chronic
patients in four focus groups, a preliminary instrument with
36 items grouped into six dimensions was developed. Three
samples of patients were enrolled during the whole process:
1) 12 patients to assess feasibility and pertinence of items;
2) 150 patients for item reduction; and 3) 455 patients for
psychometric properties assessment of the instrument. The
latter two were stratiﬁed by gender, age, and main disease
(type 2 diabetes, hypertension, osteoarthritis, benign prostate
hyperplasia, chronic obstructive pulmonary disease/asthma,
depression, and migraine). Additional measures were gath-
ered for concept validity: clinical and treatment information,
patient and clinician assessment of treatment tolerability and
effectiveness, treatment satisfaction (Treatment Satisfaction
Questionnaire for Medication [TSQM]), and therapeutic
compliance (Morisky-Green). Feasibility, reliability, and
validity (content, discriminant, construct, and concurrent)
were assessed.
Results: Factor analysis item reduction resulted in a 17-item
questionnaire with six dimensions: treatment effectiveness,
convenience of use, impact on daily activities, medical care,
global satisfaction, and undesirable side effects. Unidimen-
sional scales (Cronbach’s alpha ranging 0.813–0.912) were
correlated, and allowed computation of a summary compos-
ite score (alpha = 0.890). SATMED-Q dimensions showed
moderate but signiﬁcant correlations with TSQM dimensions
(0.577–0.680). Differences between tolerability and effective-
ness groups were found, depending on dimension and
whether the clinician or the patient were informing. Thera-
peutic compliance groups showed differences in some treat-
ment satisfaction dimensions.
Conclusions: The SATMED-Q is a reliable and valid
measure of treatment satisfaction, structured in six dimen-
sions, and a summary composite score. Additional work is
needed to assess sensitivity to change.
Keywords: daily medical care, development, medicines,
patient, psychometric properties, SATMED-Q, treatment
satisfaction, validation.
Introduction
In recent years, there has been a series of health
changes in the industrialized countries, directly result-
ing in the introduction of new concepts or elements to
be considered in the evaluation and appraisal of health
care. Among these changes, mention must be made of
the spectacular increase in life expectancy, with the
consequent aging of the population. This phenomenon
is largely attributable to advances in medicine, and has
resulted in changes in mortality and morbidity.
In the treatment of chronic illnesses, the traditional
measures of morbidity and mortality, together with
other biomedical parameters, only partially evaluate
the effectiveness of drugs and other medical inter-
ventions which, while prolonging patient life, do not
offer a cure. When the administered treatments do not
modify the survival rates, when the differences among
them are not dramatic, and when the treatments and
other medical interventions produce serious side effects
for months or even years, the need arises to evaluate
effectiveness in other terms [1]. The investigation
of health outcomes—a relatively recent discipline—
focuses on the measurement of disease and treatment
impact upon patient perceived health, among other
things, and provides an answer to these new require-
ments of modern medicine [2,3].
Patient satisfaction is related to all aspects of health
care that are of relevance to health. The concept
includes satisfaction with both the medical care
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received, and with the speciﬁc treatments prescribed
[4,5]. Patient satisfaction can be conceived as a
pyramid where satisfaction with health care is located
at the base. This element is related to all aspects of the
care received, and includes patient satisfaction with
access to medical care, physician behavior and techni-
cal competence, the services provided, the costs,
and the treatment selected. At an intermediate level
lies global treatment satisfaction, which includes all
aspects relating to the latter: effectiveness, conve-
nience, undesirable effects, follow-up, etc. Lastly, at
the tip of the pyramid we ﬁnd satisfaction with the
medication received—this being the evaluation made
by the patient of the process of administering the medi-
cation, and the results associated with it [5].
Satisfaction with medication and with medical
treatment appears to be related to patient adherence or
compliance with treatment, and constitutes a quality
indicator that can be used to improve health care, and
which affects patient preferences [4,6–11]. In addition,
knowledge of the degree of satisfaction with treatment
can contribute to predict treatment compliance and
help clinicians take decisions. Consequently, measure-
ment of this parameter is one of the health outcomes
which must be complied with in both daily clinical
practice and in biomedical research [12]. Until rela-
tively recently, most instruments designed to measure
patient satisfaction with medical treatment were spe-
ciﬁc to a given disease or clinical situation. This obvi-
ously not only limited their use, but also precluded
comparisons of patient satisfaction with medical treat-
ment between different diseases or medical situations.
Recently, Atkinson et al. [13] have developed a generic
instrument designed to measure satisfaction with phar-
macological treatment for any disease: the Treatment
Satisfaction Questionnaire for Medication (TSQM), of
which an abridged version is available [14]. The initial
version included four dimensions: side effects, effec-
tiveness of the medication, convenience of use (CU),
and global satisfaction. Nevertheless, it did not con-
template other dimensions such as satisfaction with
medical care or the impact of medication on daily
living activities—these being relevant aspects within
the satisfaction with treatment construct (particularly
as they might refer to the capacity to predict adherence
to therapy), because they are viewed by patients as
attributes of medical treatment [15–18].
Because of the possible limitations of the TSQM in
capturing all patient perceptions and in evaluating all
the dimensions necessary to adequately measure the
level of satisfaction with drug treatment, the present
study was designed with the aim of developing a
generic instrument for measuring patient satisfaction
with chronic drug-based treatment: The SATMED-Q
questionnaire. The idea is to offer a multidimensional
generic questionnaire, of limited extent, feasible and
easy to self-administer, and with good metric proper-
ties (reliability and validity). Likewise, the question-
naire is designed for use with patients presenting any
illness and subjected to any type of prolonged pharma-
cological treatment, although only a limited range of
pathologies have been considered. As a result, we hope
to develop a measurement instrument that can help
clinicians to better orient the management of chronic
illnesses toward decisions that in accordance with
patient satisfaction will favor treatment compliance
and effectiveness. The questionnaire has been devel-
oped assuming the Classical Test Theory framework.
Method
Panel of Experts
The questionnaire development process began with
the selection of a panel of experts composed of two
experts in psychometrics, a clinical pharmacologist, an
expert in health outcomes research, two clinical phy-
sicians, and an interviewer. In the patient recruitment
and assessment phase, four additional clinical physi-
cians were incorporated. The panel of experts super-
vised all phases of the development and validation of
the questionnaire.
A literature review and compilation of the articles
published on satisfaction, treatment satisfaction, ser-
vice satisfaction, and health-related quality of life in
both the health-care science and social science sett-
ings (Medline, Embase, Current Contents, Cochrane
Library) were ﬁrst carried out. A review and compila-
tion were also made of the existing questionnaires on
satisfaction with treatment, and the TSQM [13] was
selected as a reference instrument.
Taking these reviews as a starting point, the panel of
experts generated an initial series of questions relating
to the following aspects of treatment with drugs:
global satisfaction, effectiveness, convenience of appli-
cation, undesirable side effects (UE), expectations,
available clinical options, recommendation disposi-
tion, short-term consequences, long-term conse-
quences, adherence, satisfaction with medical care,
and impact on daily life.
Focus Groups
Four discussion groups were then formed with patients
to document their opinion on the pertinence of the
dimensions and items initially contemplated by the
panel of experts, and to collect additional information
on those aspects of treatment which the experts might
have missed. In all groups, the patients were questioned
about the following: 1) the time during which they had
been taking the medication; 2) their concern about
having to take medicines on a permanent basis; 3) the
possible side effects of the medication; 4) the effective-
ness of the medication in treating their illness; 5) their
“adjustment” to the medication; 6) convenience-
914 Ruiz et al.
inconvenience of taking the medication; 7) the aspects
ofmedication proving inconvenient or bothersome; and
8) their degree of satisfaction with the medication
received.
The ﬁrst group comprised three males and three
females, all permanent residents in a nursing home
for the elderly in the Community of Madrid, and all
receiving chronic drug treatment. The second group
likewise comprised three males and three females from
a second nursing home for the elderly in the Commu-
nity of Madrid, and receiving chronic drug treatment.
The third group consisted of four women receiving
hormone replacement therapy started 7 to 10 years
earlier. Lastly, the fourth group consisted of ﬁve hyper-
tensive patients (four males and one female) subjected
to treatment for 1 to 10 years. Thus, a total of 21
subjects receiving chronic drug treatment were
involved. The patient comments and answers were
transcribed as literally as possible.
Item Generation
Combining the initial considerations of the panel of
experts and the information obtained from the discus-
sion groups, we deﬁned the dimensions considered to
be relevant for inclusion in the questionnaire with the
generation of a comprehensive list of items in afﬁrma-
tion format, reﬂecting as far as possible the expressions
directly recorded from the patients participating in the
discussion groups. The items were designed taking care
to ensure that they referred to a single concept (pre-
dominantly in an afﬁrmative sense), avoiding double
negations and ambiguity, and adopting a ﬁrst-person
format. The answers were scored on a Likert-type scale
from 0 to 4, as follows: 0 = “No, not at all”; 1 = “A
little bit”; 2 = “Neither a lot, nor a little”; 3 = “Quite
a lot”; 4 = “Yes, very much.”
One or two items were formulated for each of the
following aspects: 1) global satisfaction with current
treatment; 2) effectiveness of treatment; 3) information
on the disease; 4) discomfort with treatment (including
side effects); 5) design/appearance of the product; 6)
treatment convenience; 7) intent to continue with the
treatment; 8) ease/difﬁculty of treatment administra-
tion; 9) information on the treatment; 10) treatment
ﬂexibility (when, where); 11) convenience when not
used (transport, storage, etc.); 12) patient’s self-
conﬁdence in ability to use the treatment; 13) compari-
son with other treatment; 14) ease of drug purchase;
15) satisfaction with treatment planning; 16) prompt-
ness of treatment action; 17) safety; 18) duration of
treatment; 19) number of doses; 20) degree to which
treatment meets patient expectations; 21) proximity to
ideal treatment; and 22) recommendation to friends.
The initially formulated items were evaluated by a
semantic discussion and screening process, resulting
in 36 items grouped into six sections or dimensions:
effectiveness of the medication and its capacity to treat
the disease and alleviate symptoms (ﬁve items), conve-
nience of the medication and ease of administration
(six items), impact of the medication on patient daily
life (four items), medical care and follow-up of the
illness (four items), UE of the medication (eight items),
general opinion and beliefs relating to the medication
and health condition (nine items).
Subjects
Because the new instrument aims to measure satisfac-
tion with pharmacological treatment in patients with
different diseases, its development and validation were
based on the selection of patients diagnosed with
disorders showing a high prevalence in our setting,
such as type 2 diabetes mellitus (DM2), arterial hyper-
tension, arthrosis, benign prostate hyperplasia (BPH),
chronic obstructive pulmonary disease (COPD)/
asthma, depression, and migraine.
For patient recruitment, the researchers conducted
probabilistic sampling in six hospital centers in the city
of Madrid and in the Community of Madrid: Centro
de Salud Mendiguchía Garriche in Leganés, Centro de
Salud Orcasitas in Madrid, Clínica Madrid in Fuenla-
brada, Centro de Salud in Ciempozuelos, Hospital
Gregorio Marañón in Madrid, and Centro Ambulato-
rio de Atención Primaria in Parla.
The patients were selected from among those visit-
ing the center and who met the following study in-
clusion criteria: outpatients of either sex and over
18 years of age, diagnosed with one of the aforemen-
tioned diseases, with two or more months of treatment
for the disorder at the time of selection, the ability to
understand and answer the health questionnaires
included in the study, and willing to sign the informed
consent form.
The study, of a multicenter, cross-sectional and
observational design, was conducted under the condi-
tions of normal clinical practice as refers to disease
treatment, and all patients were requested to grant
informed consent to utilization of their data and inclu-
sion of the latter in a database. The study protocol was
approved by the Clinical Research Ethics Committee
of Universidad Autónoma de Madrid.
Three different samples were used: 1) pilot sample:
composed of 12 randomly recruited patients; 2) reduc-
tion sample: selected taking three segmentation criteria
into account: gender (male, female); age (<65 years,
>65 years) and pathology (DM2, hypertension, arthro-
sis, BPH, COPD/asthma, depression, and migraine);
and 3) validation sample: selected taking into account
the same segmentation criteria as in the reduction
sample.
The size of the pilot sample was considered sufﬁ-
cient to evaluate feasibility and pertinence of the ques-
tionnaire, and to determine whether the items were
clearly understood by the patients.
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The size of the reduction sample was determined
based on the criterion of Rummel [19], whereby the
ratio subjects/variables should be no less than 4/1.
Considering the number of items of the ﬁrst version of
the questionnaire, and moreover taking into account
that some subjects could give nonevaluable answers, a
minimum of 150 patients was considered advisable.
Consequently, we decided to select six subjects for each
combination of gender (two levels), age (two levels),
and pathology (seven levels): this represented a total of
156 individuals, taking into account that women
cannot be included in the BPH group. Patient selection
was random and sequential, until the indicated subject
quotas were covered.
The size of the validation sample was calculated
based on the same criteria: because the ﬁnal question-
naire was to contain no more than three questions
per dimension (18 questions maximum), the sample
required to apply factor analysis was found to be 72
patients. Nevertheless, the sample size was overdimen-
sioned to allow statistical comparisons between mean-
ingful groups related to the validity study: we decided
to select a minimum of 50 patients (25 males and 25
females) corresponding to each of the seven patholo-
gies considered in the study—representing a minimum
of 350 patients in total.
The reduction sample ﬁnally comprised 150
patients. Although a similar patient quota was
assigned to each of the participating centers, recruit-
ment was carried out competitively among the centers
to accelerate the patient recruitment process. For this
reason, the quotas contemplated in the original design
(six subjects per stratum) could not be precisely
covered; nevertheless, the deviations were not consid-
ered to be relevant to the effects of representativeness.
The validation sample comprised 455 patients. Table 1
reports the number of cases sampled per stratum, in
addition to the mean age, mean body mass index, and
the distributions corresponding to the variables of race
and educational level.
Reduction of the Questionnaire
The initial 36-item questionnaire was administered to
the pilot sample. Patient comments and information
about comprehension and reading problems with the
proposed items were collected.
The revised questionnaire incorporating the contri-
butions of the pilot sample was in turn administered
to the reduction sample. The information obtained
from this sample was then used for the following: 1) to
check adjustment of the patient responses to the struc-
ture (dimensions or subscales) proposed by the group
of experts; 2) to assess the metric properties of the
items; and 3) to reduce the number of questions to a
maximum of three per dimension.
Reduction of the questionnaire and determination
of the underlying dimensions were carried out via a
sequence of exploratory factor analyses, and based on
the analysis of internal consistency. The factor analyses
made use of two extraction methods: principal com-
ponents and principal axes; and two rotation methods:
varimax (orthogonal) and oblimin (oblique) [20].




testing sample (n = 455)
Age (years): mean (SD) 58.96 (15.73) 62.07 (13.61)
Sex, male: n (%) 79 (52.7) 229 (50.3)
BMI (kg/m2): mean (SD) 26.98 (4.13) 27.77 (4.71)
Race: n (%)
Caucasian 148 (98.7) 443 (97.4)
African 1 (0.6) 6 (1.3)
Other 2 (1.3) 6 (1.3)
Education: n (%)
No high school diploma 76 (50.3) 247 (54.3)
High school graduate 27 (17.9) 106 (23.2)
Professional training diploma 19 (12.6) 42 (9.2)
College graduate 21 (13.9) 54 (11.8)
Unknown 8 (5.3) 6 (1.3)
No. of patients by disease
Male Female Male Female
<65 (%) 65 (%) <65 (%) 65 (%) <65 (%) 65 (%) <65 (%) 65 (%)
Diabetes 5 (3.3) 6 (4.0) 5 (3.3) 4 (2.7) 17 (3.7) 16 (3.5) 7 (3.7) 21 (4.6)
Hypertension 9 (6.0) 5 (3.3) 5 (3.3) 7 (4.7) 21 (4.6) 27 (5.9) 27 (5.9) 27 (5.9)
Osteoarthritis 4 (2.7) 6 (4.0) 6 (4.0) 7 (4.7) 17 (3.7) 18 (3.9) 17 (3.7) 18 (3.9)
BPH 6 (4.0) 7 (4.7) — — 16 (3.5) 24 (5.3) — —
COPD/asthma 5 (3.3) 6 (4.0) 5 (3.3) 5 (3.3) 13 (2.9) 16 (3.5) 15 (3.5) 15 (3.5)
Depression 4 (2.7) 6 (4.0) 6 (4.0) 7 (4.7) 15 (3.3) 14 (3.1) 24 (5.3) 17 (3.7)
Migraine 8 (5.3) 2 (1.3) 13 (8.7) 1 (0.7) 10 (2.2) 5 (1.1) 19 (4.2) 9 (2.0)
Total 41 (27.3) 38 (25.3) 40 (26.7) 31 (20.7) 109 (23.9) 120 (26.4) 119 (26.2) 107 (23.5)
BMI, body mass index; BPH, benign prostate hyperplasia; COPD, chronic obstructive pulmonary disease; 65, 65 years old.
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Heuristics for determining the optimum number of
factors comprised the Kaiser K1 rule, the percentage of
variance accounted for, and the magnitude of the
eigenvalues after rotation [21–23]. A number of deci-
sion rules were used, because of the tendency of all of
them to either underestimate or overestimate the
correct number of factors in different contexts [21,24–
26]. Internal consistency was evaluated by means of
Cronbach’s alpha reliability coefﬁcient, and the change
in alpha coefﬁcient after deleting each item from the
scale [23].
In this reduction of the length of the questionnaire
and analysis of dimensionality, we adopted the propos-
als of Gorusch and Russell [27–29]. First, we discarded
those items with a clear ﬂoor or ceiling effect (i.e.,
items with more than 50% of answers concentrated in
the ﬁrst or last answer category). Second, an explor-
atory factor analysis was made with the 36 items of the
scale to determine the number of underlying factors
or dimensions (subscales). Lastly, we analyzed the
dimensionality (factor analysis) and internal consis-
tency (Cronbach’s alpha coefﬁcient) of each subscale,
assuming all of them to be unidimensional.
In this latter step, those items with lower loading in
the ﬁrst dimension, or cross-loading in more than one
dimension were discarded. Items with lowest contribu-
tion to the scale overall alpha coefﬁcient were also
proposed for deletion. Items were discarded one by
one until leaving three items in each subscale (except
the subscale medical care, which was left with two
items). After each deletion, the same analyses were
repeated until the unidimensional structure of each
subscale was found to be stable, without further
improvement in the alpha coefﬁcient.
Finally, an exploratory factor analysis was carried
out with all the reﬁned subscales to check that the
structure remained stable. All statistical analyses were
made using the SPSS version 14.0 statistical package.
Psychometric Properties of the Final Version
The abridged or ﬁnal version of the questionnaire was
included in a case report form (CRF), together with
clinical information of relevance for the patient, socio-
demographic information, a Spanish adaptation of the
TSQM [13], the Morisky-Green compliance question-
naire [30], and the clinician and patient evaluations of
tolerability and effectiveness.
The CRF was distributed in the validation sample.
The data obtained from this sample were then used
for the following: 1) to assess the metric properties of
the questionnaire; and 2) to elaborate norms for the
Spanish population.
The following metric properties of the ﬁnal ques-
tionnaire were studied: 1) feasibility: administration
time, ﬂoor and ceiling effects, percentage of missing
values in each item; 2) reliability: internal consistency,
evaluated by means of Cronbach’s alpha coefﬁcient
and the Pearson correlation coefﬁcient between items
and between each item and the total composite score;
test–retest (temporal stability), evaluated by correlat-
ing two administrations of the questionnaire based on
the Pearson correlation coefﬁcient and intraclass cor-
relation coefﬁcient (ICC) [31–33]; 3) content validity:
ensured by the panel of experts and by patient consul-
tation in the four discussion groups. In addition, we
used the evaluations of six referees, whose degree of
consensus in assigning items to dimensions was estab-
lished by the coefﬁcient of Rovinelli and Hambleton
[34]; 4) construct validity: the structure in dimensions
of the answers gathered with the ﬁnal questionnaire
was established by exploratory and conﬁrmatory
factor analysis. With both types of analysis the aim
was to contrast the dimensional structure of the ﬁnal
scale and the allocation of each item to its respective
dimension; 5) concurrent validity: correlations were
made of the SATMED-Q scores with those of the treat-
ment satisfaction questionnaire (TSQM) [13] and the
Morisky-Green compliance questionnaire [30]; and 6)
discriminant validity: an analysis was made of the
capability of each item to discriminate between the
25% of subjects with the lowest scores and the 25%
with the highest scores (established from the total com-
posite scale scores), and of the capability of each sub-
scale and of the composite scale to discriminate
between groups of patients formed from evaluations
of effectiveness and tolerability conducted by the
clinicians and by the patients. These evaluations were
carried out on a 4-point ordinal scale (poor, accept-
able, good, and excellent), according to patient and
clinician perceptions. All analyses were made using the
SPSS version 14.0 (SPSS, Chicago, IL) statistical
package and Amos 6.0 (SPSS).
Scoring
Summing up the direct scores of the items yields a total
composite score ranging between 0 and 68. The
observed total composite score can be transformed to
a more intuitive and easier to understand metric with a












where Ymax = 68 (maximum total score); Ymin = 0
(minimum total score); Yobs = total score obtained by
the patient; and Y = transformed score. A similar




The four discussion groups yielded coincident results.
Good adjustment to medication was observed in all
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cases: most of the participants claimed medication to
have become just another part of daily routine.
The ﬁrst aspect considered to be fundamental for
satisfaction with the medication was effectiveness,
which soon evidenced to be one of the principal moti-
vations for taking a drug. A second aspect also con-
sidered to be important was conﬁdence in the
physician and the capacity of the latter to make himself
understood by the patient. Another aspect considered
to be relevant was patient expectations in relation to
the capacity of the drug to heal or alleviate the disease
(this being particularly apparent in the hypertensive
subjects, where those patients who had developed
hypertension as a consequence of some other disorder
trusted that the time would come when they would no
longer need the medication).
The information obtained from these groups con-
ﬁrmed that no contents of interest or relevance for
chronic patients had been obviated or left out.
Reduction of the Questionnaire
Table 2 reports the internal consistency results before
(initial scale, 36 items) and after item reduction (ﬁnal
scale, 17 items). The values recorded for Cronbach’s
alpha coefﬁcient (above 0.82 in all subscales of the
ﬁnal version) reﬂect good internal consistency. The
percentage of variance accounted for by the ﬁrst
dimension of each subscale suggests that the subscales
are one-dimensional.
The results of the factor analysis (Table 3) corrobo-
rate the presence of six dimensions (ﬁve with eigen-
values above 1, and the sixth with an eigenvalue of
Table 2 Reduction sample: internal consistency of subscales
Domains
Number of items Cronbach’s alpha
% variance explained*Initial Final Initial Final
Treatment effectiveness 5 3 0.825 0.821 65
Convenience of use 6 3 0.830 0.857 78
Impact on daily living activities 4 3 0.890 0.890 75
Medical care 4 2 0.886 0.844 76
Undesirable side effects 8 3 0.851 0.880 75
Global satisfaction 9 3 0.792 0.847 69
*Percentage of variance accounted for by the ﬁrst factor in each subscale.
Table 3 Reduction sample: exploratory factor analysis solution (oblimin rotation)
SATMED-Q
Factors
CU MC UE GS TE ID
Treatment effectiveness
Relief of symptoms -0.064 0.155 -0.041 -0.005 -0.911 0.164
Time to start working -0.033 -0.282 -0.051 0.243 -0.713 -0.240
Feel better 0.393 0.070 0.083 -0.084 -0.614 -0.201
Convenience of use
Ease of medication use 0.759 -0.016 -0.192 0.158 0.077 -0.055
Convenience of medication use 0.947 -0.004 0.059 0.026 -0.003 0.070
Frequency of medication use 0.553 -0.044 -0.377 0.097 -0.085 -0.135
Impact on daily living/activities
Leisure activities 0.073 0.181 -0.057 0.056 -0.102 -0.725
Personal hygiene -0.006 -0.031 0.038 -0.034 0.138 -0.975
Usual daily activities -0.042 0.155 -0.041 0.070 -0.148 -0.795
Medical care
Medical disease information 0.003 0.952 0.024 0.050 0.021 -0.071
Treatment disease information -0.025 0.943 -0.035 0.039 -0.048 -0.068
Global satisfaction
Conﬁdent in treatment adherence 0.089 0.042 0.112 0.888 0.015 0.116
Pleasure of being treated 0.000 0.025 -0.067 0.867 -0.008 -0.087
Global satisfaction 0.001 0.022 -0.138 0.758 -0.050 -0.107
Undesirable side effects
Impact on physical activities -0.028 -0.005 0.931 0.112 0.033 0.013
Impact on leisure activities -0.080 0.017 0.933 0.007 -0.002 0.033
Impact on daily living activities 0.051 -0.022 0.887 -0.147 -0.036 -0.069
Eigenvalues 6.548 2.670 1.538 1.390 1.169 0.979
Percentage of variance explained (%) 38.517 15.708 9.046 8.178 6.878 5.758
Factor correlation matrix
Medical care 0.000
Undesirable side effects -0.344 -0.002
Global satisfaction 0.388 0.155 -0.381
Treatment effectiveness -0.226 -0.170 0.149 -0.263
Impact on daily living/activities -0.280 -0.276 0.247 -0.269 0.295
CU, convenience of use; GS, global satisfaction; ID, impact on daily living/activities; MC, medical care;TE, treatment effectiveness; UE, undesirable side effects. Bold indicates the
highest factor loading for each item (row) in the corresponding dimension (column).
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0.979), which account for 84.09% of the total avail-
able variance, with communalities ranging between
0.751 and 0.965. In the results of the factor solution
(17 items, six dimensions, oblimin rotation), it can be
seen that all the items preferentially load in their cor-
responding theoretical dimension. Only two items load
below 0.70 in their dimension (“feel better” = -0.612;
“frequency of medication use” = 0.553) and above
0.30 in a dimension other than their own (“feel bet-
ter” = -0.393 in CU; “frequency of medication
use” = -0.377 in UE). Therefore, the analysis of the
answers indicates excellent assignment of the items in
their corresponding theoretical dimensions.
Although the items of the subscale UE show a clear
ﬂoor effect (percentage of subjects in the ﬁrst response
category between 75.2% and 80.4%), the subscale has
been included in the ﬁnal questionnaire because in
addition to its other good metric properties, the
experts decided that the subscale is important for
assessing drug safety. Nevertheless, the results of the
factor analysis after excluding the three items of the
UE subscale prove equally conclusive: the analysis
yielded ﬁve dimensions (four with eigenvalues above 1,
and the ﬁfth with an eigenvalue of 0.995), which
account for 82.10% of the total variance, with com-
munalities of between 0.707 and 0.960. In the results
of the factor solution (14 items, ﬁve dimensions,
oblimin rotation), all items are seen to preferentially
load in their theoretical dimension. Only one item
loads below 0.70 in its dimension (“feel bet-
ter” = 0.630) and above 0.30 in a dimension other
than its own (“feel better” = 0.362 in CU).
Finally, the relationship between dimensions ranges
from low to moderate: the correlations among the
subscales CU, UE, and global satisfaction range
between 0.34 and 0.39; the remaining correlations are
bellow 0.30. Satisfaction measured by the subscale
medical care appears to be independent to both CU
and UE.
Psychometric Properties of the Final Version
Feasibility. The nonresponse rate in the validation
sample (455 patients) was very low: 96.7% of the
patients answered all the questions in the question-
naire. The mean response time was 4.71 minutes
(SD = 4.65). The median was 4 minutes. The fastest
patient completed the questionnaire in 1 minute, and
the slowest in 35 minutes. Only 12.6% of the patients
took more than 10 minutes to respond.
The total composite scores exhibited a negative
skewed distribution, with a mean of 75.03 and a stan-
dard deviation of 14.76. The median was 77.08. The
minimum recorded score was 17.36, and the maximum
100. The responses, for all items, were distributed along
all the proposed response categories. With the excep-
tion of the subscale UE, the distribution of the responses
showed a slight negative skewness; the item with the
most skewed distribution (willingness to continue treat-
ment) accumulated 44% of the responses in the upper
part of the scale. All distributions were unimodal.
The subscale UE accumulated the responses in the
lower portion of the scale: between 66% and 75% of
the responses were located in the category “No, not at
all.” This ﬂoor effect was also found in the reduction
sample and, in our opinion, justiﬁes the possibility of
using this subscale independently to the rest as an
indicator of situations of lack of tolerability.
Reliability. The estimation of internal consistency
(Cronbach’s alpha coefﬁcient) with the validation
sample exceeds the value of 0.81 for all subscales
(Table 4). With the total composite scale, a value of
0.879 has been obtained (0.890 when excluding the
subscale UE). The ﬁrst eigenvalue is markedly bigger
than the second on all subscales, and the ﬁrst dimen-
sion of each subscale accounts for a percentage of
variance between 73% and 90%—thus indicating that
the subscales behave in a one-dimensional manner.
To analyze the discriminative capacity of each item
considered individually, two patient groups were
created from the scores obtained in the total composite
scale. The ﬁrst group comprised the 25% of patients
with the lowest scores, although the second comprised
the 25% of patients with the highest scores. Compari-
son between these two groups with the Student t-test
yielded signiﬁcant differences for all items (t127 > 6.4
and P < 0.0005 in all cases).
The scale was administered to 128 patients a
second time several days after the ﬁrst administration
Table 4 Validation sample: internal consistency statistics
No. of items Alpha First eigenvalue Second eigenvalue % variance explained*
Treatment effectiveness 3 0.813 2.193 0.440 73
Convenience of use 3 0.861 2.351 0.393 78
Impact on daily living/activities 3 0.851 2.319 0.503 77
Medical care 2 0.885 1.794 0.206 90
Undesirable side effects 3 0.912 2.557 0.284 85
Global satisfaction 3 0.855 2.328 0.476 78
Total composite score 17 0.879
*Percentage of variance explained by the ﬁrst factor in each subscale.
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(mean = 3; SD = 1.015; minimum = 1; maximum =
9). Cronbach’s alpha coefﬁcient on occasion of this
second administration was 0.889 for the total com-
posite scale (17 items). The correlation between
administrations was 0.945, and the ICC was 0.943,
with a 95% conﬁdence interval of (0.928–0.957).
The mean total composite score was 50.28
(SD = 9.80) for the ﬁrst administration, and 50.24
(SD = 9.94) for the second. The difference between
these means was not signiﬁcant (t127 = 0.37,
P = 0.716). It can be concluded therefore that the
scale remains stable between measurements.
Content validity. Although content validity was war-
ranted by the initial work of the panel of experts, six
independent referees were asked to classify each item
of the ﬁnal scale in the dimension where they consid-
ered it to belong. Each referee should score items in the
six possible dimensions, assigning a value of 1 if the
item measures the dimension, -1 if the item does not
measure the dimension, and 0 if it is not clear. When all
referees agree and items belong to a unique dimension,
a given item should attain an average value of 1 in the
dimensions it belongs to, and -1 in the alternative
dimensions. After applying the coefﬁcient of Rovinelli
and Hambleton to the responses of the referees, the
highest coefﬁcients for each item were obtained in their
corresponding theoretical dimension, with values
ranging from 0.63 (item 12) to 0.93 (items 16 and 17).
In addition, very low coefﬁcients were obtained for all
items in the remaining dimensions, with values ranging
between -0.42 and 0.28. These results indicate excel-
lent agreement among the referees, and conﬁrm correct
correspondence between referee assessment and the
initial allotment of the items in their respective theo-
retical dimensions.
Construct validity. The dimensionality of the ques-
tionnaire has again been analyzed with the data
obtained from the validation sample. The results of the
exploratory factor analysis corroborate the presence of
six dimensions (ﬁve with eigenvalues above 1, and the
sixth with an eigenvalue of 0.876), which account for
80.83% of the total variance, and communalities
between 0.720 and 0.905. In the results of the factorial
solution (17 items, six dimensions, oblimin rotation;
see Table 5), all items are seen to preferentially load
in their theoretical dimension. Only two items load
below 0.70 in their dimension (“relief of symp-
toms” = 0.681; “global satisfaction” = 0.612), and
none load above 0.30 in a dimension other than their
own. Therefore, the analysis of the answers indicates
Table 5 Validation sample: exploratory factor analysis solution (oblimin rotation)
SATMED-Q
Factors
ID UE CU MC GS TE
Treatment effectiveness
Relief of symptoms 0.117 0.031 -0.051 0.072 0.168 0.681
Time to start working -0.123 0.003 0.095 -0.005 -0.018 0.947
Feel better 0.189 0.014 -0.035 0.023 -0.003 0.725
Convenience of use
Ease of medication use 0.021 0.000 0.891 0.048 -0.062 0.043
Convenience of medication use -0.037 -0.035 0.889 -0.011 0.127 -0.074
Frequency of medication use 0.072 -0.032 0.794 -0.038 0.025 0.075
Impact on daily living/activities
Leisure activities 0.844 -0.046 -0.048 -0.024 0.167 -0.025
Personal hygiene 0.753 0.106 0.221 0.051 -0.095 0.020
Usual daily activities 0.909 -0.060 -0.062 0.021 0.005 0.073
Medical care
Medical disease information -0.012 -0.001 -0.059 0.963 -0.006 -0.010
Treatment disease information 0.003 -0.019 0.055 0.926 0.018 0.013
Global Satisfaction
Conﬁdent in treatment adherence -0.006 0.110 0.052 0.049 0.916 -0.075
Pleasure of being treated 0.061 -0.102 0.080 0.016 0.793 0.099
Global satisfaction 0.087 -0.140 -0.023 -0.003 0.612 0.290
Undesirable side effects
Impact on physical activities 0.018 0.912 -0.017 -0.006 0.016 -0.015
Impact on leisure activities -0.020 0.948 0.000 -0.009 0.016 0.002
Impact on daily living activities 0.001 0.900 -0.028 -0.008 -0.005 0.051
Eigenvalues 6.050 2.611 1.776 1.383 1.044 0.876
Percentage of variance explained (%) 35.591 15.361 10.449 8.135 6.144 5.153
Factor correlation matrix
Undesirable side effects -0.047
Convenience of use 0.314 -0.197
Medical care 0.264 -0.095 0.120
Global satisfaction 0.421 -0.164 0.285 0.274
Treatment effectiveness 0.506 -0.082 0.245 0.269 0.447
CU, convenience of use; GS, global satisfaction; ID, impact on daily living/activities; MC, medical care;TE, treatment effectiveness; UE, undesirable side effects. Bold indicates the
highest factor loading for each item (row) in the corresponding dimension (column).
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excellent assignment of the items in their correspond-
ing theoretical dimensions.
In the same way as in the reduction sample, valida-
tion of the items of the subscale UE reveals a marked
ﬂoor effect. On excluding the three items corresponding
to that subscale from the analysis, the results reveal
the presence of ﬁve dimensions (four with eigenvalues
above 1, and the ﬁfth with an eigenvalue of 0.875),
which account for 79.56% of the total variance, and
communalities between 0.688 and 0.905. In the results
of the factor solution (14 items, ﬁve dimensions,
oblimin rotation), all items were seen to preferentially
load in their theoretical dimension.Only two items load
below 0.70 in their dimension (“relief of symptoms” =
0.675; “global satisfaction” = 0.661), and none load
above 0.30 in a dimension other than their own.
The relationship between dimensions ranges from
low to moderate: the strongest correlations are found
between the subscale impact on daily living activities
and the subscales global satisfaction (0.42) and treat-
ment effectiveness (0.51). Surprisingly, satisfaction
associated to impact on daily living activities does not
appear to be associated to UE.
Lastly, Figure 1 shows the result of the conﬁrmatory
estimation of the proposed theoretical structure of the
questionnaire, using the generalized minimum squares
method. All loadings are signiﬁcant (P < 0.001), as
are all the correlations among factors (P < 0.05),
except the correlation between UE and impact on daily
living activities (P = 0.051). The goodness of ﬁt statis-
tics indicate a good or very good ﬁt: GFI = 0.938;
AGFI = 0.909; CFI = 0.860; RMR = 0.069 and
c2/df = 2.225. Only the RMSEA statistic = 0.053
shows a moderate value. It was needed to ﬁx the
variance error of the second indicator of the dimension
medical care, to avoid estimation taking a value
outside range (Heywood case); a value of 0.01 was
imposed, taking as reference the uniqueness estima-
tions of the exploratory factor analysis. This result was
to be expected: because the dimension only includes
two indicators, the estimation of the error variance




















































































Figure 1 Conﬁrmatory factor analysis esti-
mates. CU, convenience of use; GS, general sat-
isfaction; ID, impact on daily activities; MC,
medical care; TE, treatment effectiveness; UE,
undesirable side effects.
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Concurrent validity. The SATMED-Q scores signiﬁ-
cantly correlate with the scores of the Spanish version
of the TSQM (Table 6): a correlation of 0.74 was
obtained between the total composite scores of both
scales, with correlations ranging from 0.58 to 0.68
between dimensions of similar contents (P < 0.0005 in
all cases).
A signiﬁcant relationship was also found between
the scores of the SATMED-Q and those of the
Morisky-Green compliance test. The correlations
proved signiﬁcant for both the total composite score
and for all the subscales except medical follow-up and
UE—which only reached marginal signiﬁcance.
Discriminant validity. To evaluate the degree to which
the dimensions of the SATMED-Q discriminate
between groups which are expected to differentiate, we
used the effectiveness and tolerability assessments
made by both the clinicians and the patients, on a
4-point ordinal scale: poor, acceptable, good, excel-
lent. The observed relationship between clinician
and patient assessment is important: tau-b = 0.59
(P < 0.0005) in the case of effectiveness, and tau-
b = 0.66 (P < 0.005) in the case of tolerability (in both
instances with N = 453).
The assessments of the clinicians were used to estab-
lish four groups of effectiveness and four groups of
tolerability (poor, acceptable, good, excellent). The
same procedure was applied in the case of patient
assessment. Table 7 reports the results of each of these
groups in the SATMED-Q. The comparisons made
reveal signiﬁcant differences that depend on the dimen-
sion evaluated and on the evaluator (clinician or
patient).
The groups of effectiveness formed with the assess-
ments of the clinicians differ in the total composite
score and for all the subscales (P < 0.0005 in all cases)
except convenience (P = 0.315) and UE (P = 0.220).
The groups of effectiveness conformed with the assess-
ments of the patients yield similar results: very signiﬁ-
cant differences are found in the total composite score
and for all the subscales (P < 0.0005) except medical
follow-up (P = 0.051) and UE (P = 0.034). The ten-
dency of the observed differences is always the same: as
perceived effectiveness increases, so do the satisfaction
scores (the linear component being the only one to
reach signiﬁcance in all cases where differences are
observed). The Kendall tau-b correlation coefﬁcients
between the satisfaction scores and the effectiveness
assessments show relationship patterns almost identi-
cal to those obtained with the analysis of variance: the
evaluations made by the clinicians correlate with the
level of satisfaction in all dimensions (P < 0.0005)
except convenience (P = 0.969) and UE (P = 0.366). In
turn, the evaluations made by the patients correlate
with their level of satisfaction in all dimensions
(P < 0.0005 in all cases except medical follow-up,
where P = 0.008).
The groups of tolerability formed with the assess-
ments of the clinicians differ in the total composite
score and for all the subscales (P < 0.001 in all cases)
except convenience (P = 0.088), impact of the medica-
tion (P = 0.168) and medical follow-up (P = 0.036).
The groups of tolerability formed with the assessments
of the patients differ in the total composite score and
for all the subscales (P < 0.0005) except medical
follow-up (P = 0.330). The tendency of the differences
found in the most relevant dimension in this context
(UE) is linear: as perceived tolerability increases, so
does satisfaction in relation to UE. The Kendall tau-b
correlation coefﬁcients between the satisfaction scores
and the tolerability assessments show relationship pat-
terns almost identical to those obtained with the analy-
sis of variance: the evaluations made by the clinicians
correlate with the level of satisfaction in all dimensions
(P < 0.0005) except convenience (P = 0.257), impact
of medication (P = 0.207), and medical follow-up
(P = 0.110). In turn, the evaluations made by the
patients correlate with their level of satisfaction in all
dimensions (P < 0.0005) except medical follow-up
(P = 0.127).
Lastly, the dimension convenience allows discrimi-
nation of the level of satisfaction associated to the
different forms of drug administration. In the global
validation sample, 83.4% of the patients were receiv-
ing medication via the oral route, although 12.4%
received inhaled treatment, and 4.2% received medi-
cation via the parentheral route. The mean scores
Table 6 Correlations between SATMED-Q dimensions and TSQM and Morisky-Green compliance
SATMED-Q
TSQM
Effectiveness Side effects Convenience of use Global satisfaction Total score Morisky-Green
Treatment effectiveness 0.68 0.19 0.32 0.67 0.61 0.20
Convenience of use 0.32 0.34 0.68 0.37 0.56 0.13**
Impact on daily living/activities 0.44 0.19 0.28 0.55 0.50 0.15***
Medical care 0.19 0.02NS 0.11** 0.28 0.19 0.09*
Undesirable side effects 0.18 0.58 0.24 0.25 0.43 0.22
Global satisfaction 0.60 0.27 0.41 0.68 0.66 0.09*
Total composite score 0.61 0.39 0.51 0.70 0.74 0.22
P < 0.0001 in all cases, except: *P < 0.05, **P < 0.01, ***P < 0.001.
NS, non-signiﬁcant. Bold indicates the correlation of each SATMED-Q dimension with the congruent TSQM dimension, which should be the highest in the column.
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obtained on the convenience subscale by these three
subject groups were 75.6, 78.87, and 44.7, respec-
tively. Patient satisfaction relating to convenience with
the medication administered via the parentheral route
was signiﬁcantly lower than for oral dosing
(P = 0.003) and inhaled treatment (P < 0.001).
Norms. The correction norms are shown in Table 8.
These norms allow us to transfer the observed metric
0 to 100 scores to the corresponding deciles in the
normative sample. For example, a woman with a total
composite score of 73 would be located in decile
4—meaning that 40% of the women in the population
report similar or lower global satisfaction as she does.
Discussion
It has become increasingly recognized that the view-
point of the patient should be taken into account when
evaluating a medical treatment. One domanin of such
a patient-oriented evaluation is patient satisfaction
with treatment or treatment satisfaction.
Treatment satisfaction is a relatively recent area of
interest within health outcomes research, and appears
to be increasingly used as a patient-reported outcome
when testing new or existing treatments [35]. Patient
satisfaction with the medication received is of growing
concern in clinical practice.On one hand, this is because
satisfaction helps evaluate the goodness and conve-
nience of the medication provided. On the other hand,
the fact that treatment satisfaction is associated to
increased patient adherence to therapy and to a greater
patient desire to continue using the drug [36,37] may
help predict treatment compliance and improve effec-
tiveness of the administered therapy—with closer
follow-up of those patients expected to adhere less to
treatment.
In fact, in recent years, evaluations have been made
of satisfaction with treatment for different pathologies
and involving different drugs based on the use of spe-
ciﬁc measurement instruments [38–42], in an attempt
to obtain complementary data to facilitate improved
decision-making in correctly treating patients. Mea-




Clinician assessment Patient assessment Clinician assessment Patient assessment
N Mean SD N Mean SD N Mean SD N Mean SD
Treatment effectiveness Bad 14 39.29 30.56 22 33.71 26.29 7 70.24 29.99 17 61.76 25.69
Fair 89 62.73 25.25 92 58.33 23.15 44 60.98 21.55 66 60.48 23.54
Good 215 68.99 19.11 247 72.98 16.06 206 68.49 21.57 246 70.09 19.80
Excellent 131 81.49 16.09 87 85.44 16.82 192 74.78 21.26 119 78.01 22.17
Convenience of use Bad 14 75.60 17.74 22 68.94 23.74 7 84.52 17.63 17 63.24 32.55
Fair 90 77.59 21.15 94 69.15 26.38 44 74.05 16.98 67 71.02 23.32
Good 216 72.57 23.72 248 74.13 22.20 207 71.94 24.05 248 71.87 22.76
Excellent 132 75.82 23.97 87 83.33 19.77 194 77.23 23.34 119 83.96 19.74
Impact on daily living/activities Bad 14 45.24 30.26 22 40.15 28.60 7 76.19 30.21 17 62.25 25.36
Fair 90 59.72 27.20 94 58.33 26.15 44 60.98 23.83 67 59.08 26.89
Good 217 64.06 23.87 249 65.83 22.34 208 63.98 25.28 249 64.59 23.97
Excellent 132 73.67 19.48 87 78.16 18.99 194 67.57 23.14 119 71.08 22.75
Medical care Bad 14 71.79 18.90 22 63.64 27.52 7 71.43 36.60 17 66.91 32.16
Fair 90 72.83 28.29 94 72.21 24.33 44 65.06 27.57 67 74.07 24.07
Good 217 74.06 24.04 249 74.30 23.37 208 73.92 24.55 249 73.34 23.82
Excellent 132 79.55 19.31 87 78.45 22.77 194 76.55 21.01 119 76.89 22.17
Global satisfaction Bad 14 52.98 36.92 22 44.32 33.86 7 76.19 17.63 17 68.63 16.54
Fair 90 72.78 23.93 93 68.46 21.94 44 71.02 20.53 67 69.28 23.49
Good 214 75.97 20.06 247 79.89 16.77 205 75.20 21.78 246 76.73 19.80
Excellent 130 85.58 14.78 85 88.53 15.75 192 81.25 20.41 117 84.76 21.37
Undesirable side effects Bad 14 89.88 13.15 22 82.20 26.51 7 73.81 26.10 17 61.76 27.33
Fair 90 88.89 21.85 94 87.15 22.15 44 78.03 25.17 66 85.10 18.23
Good 216 86.77 21.45 248 88.24 19.42 206 87.62 20.36 248 87.53 20.97
Excellent 132 91.35 16.10 87 93.68 14.60 195 92.61 16.58 120 97.15 9.63
Total composite score Bad 14 63.29 19.30 22 55.49 17.29 7 75.40 14.56 17 64.09 17.55
Fair 89 71.99 16.66 91 68.60 16.62 44 68.36 13.28 65 69.43 16.11
Good 210 73.44 14.01 243 76.01 11.84 200 73.45 15.34 241 74.05 13.71
Excellent 127 80.90 11.88 83 84.21 11.71 189 78.11 13.80 116 81.66 13.06
Table 8 SATMED-Q total composite deciles by gender
Deciles
Male Female Total
Min. Max. Min. Max. Min. Max.
1 31.94 52.78 17.36 52.78 17.36 52.78
2 54.17 62.50 54.17 62.50 54.17 62.50
3 63.89 68.75 63.89 68.75 63.89 68.75
4 69.44 73.61 69.44 73.61 69.44 73.61
5 75.00 76.39 74.31 76.39 74.31 76.39
6 77.08 79.17 77.08 79.17 77.08 79.17
7 79.86 84.03 80.56 84.03 79.86 84.03
8 84.72 88.19 84.72 88.19 84.72 88.19
9 88.89 91.67 88.19 91.67 88.19 91.67
10 93.06 100.00 92.36 100.00 92.36 100.00
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surements have even been made of satisfaction among
patients included in clinical trials in the early stages of
development of a new drug, as an additional source of
information to be used in selecting the best dose of the
new drug in subsequent clinical trials [43].
The aim of this study was to develop and explore
the metric properties of a new generic instrument to
measure treatment satisfaction for use in clinical prac-
tice involving any disease and any medication. Our
ﬁndings show that the SATMED-Q questionnaire is
valid, reliable, and feasible for routine use in normal
clinical practice, both as a unidimensional instrument
(using the total composite score) and for exploring
patient satisfaction with different aspects of treatment
(for which the subscales of the instrument have also
been shown to be valid and reliable).
The results reveal that the SATMED-Q has very
good metric properties. From the feasibility perspec-
tive, the response rate is highly satisfactory (almost all
patients answered all questions), and the administra-
tion time was very brief: 4 minutes on average—thus
making it very feasible for use at any level of health
care, and particularly in primary care, where the time
available for attending patients is usually limited.
As to the reliability of the questionnaire, internal
consistency and test–retest reliability show values
above the accepted minimum standards [44], both as
relates to the total composite score and in terms of the
individually considered subscales. In addition, the indi-
vidual analysis of the items indicates that all of them
offer good discriminative capacity.
The different aspects analyzed in relation to the
validity of the questionnaire have also yielded satisfac-
tory results. Content validity (originally established by
the panel of experts) has been conﬁrmed by the pres-
ence of substantial interreferee agreement. In turn, the
study of the responses based on exploratory and con-
ﬁrmatory factor analysis corroborated the initially
proposed theoretical structure; speciﬁcally, the study
corroborated the presence of six subscales or dimen-
sions: CU, impact on daily activities, treatment effec-
tiveness, global satisfaction, UE, and medical care. The
observed relationship among the different dimensions
suggests that the scores of the different subscales can
be combined in a meaningful total composite score.
As refers to concurrent validity, the scores of the
SATMED-Q show a moderately strong correlation
(between 0.58 and 0.74) with the scores of the TSQM
(a questionnaire used as a reference). In comparison,
the observed correlations between the SATMED-Q
and the Morisky-Green treatment compliance ques-
tionnaire were appreciably weaker. Lastly, in relation
to discriminant validity, we likewise recorded satisfac-
tory results on comparing the SATMED-Q scores with
the assessment of effectiveness and tolerability made
by the clinicians and patients; as perceived effective-
ness increases, so does satisfaction, although increased
perceived tolerability is in turn associated with an
increase in satisfaction in terms of UE.
The SATMED-Q offers certain advantages over the
TSQM, particularly as refers to the presence of two
additional dimensions: one for assessing medication
impact upon daily living activities, and the other
for evaluating patient satisfaction with medical care.
These two aspects are highly appreciated by patients
and can be of help for clinicians in taking treatment
decisions [5].
Another salient aspect of the SATMED-Q, also
found in the TSQM, is its generic nature. The instru-
ment can be used to compare patient satisfaction with
drug treatment irrespective of the type of medication
or disease involved. Because of the few questionnaires
that offer this proﬁle, this particular feature makes the
instrument all the more useful.
One limitation of this study is that it involves a
cross-sectional design and is not capable of examining
casual inﬂuences of low treatment satisfaction on clini-
cally relevant outcomes. In addition, responsiveness to
change of this questionnaire was not examined in this
cross-sectional study. Prospective studies are planned
to address this issue. Another limitation of the present
study is that it only included patients with seven
chronic disorders, and extrapolation of the results to
other diseases therefore must be performed with due
caution. Drug interactions and comorbidities have not
been studied, and the present design does not allow
such inquiries. Further studies involving other diseases
and different drugs are needed to conﬁrm the ﬁndings.
A ﬁnal limitation of the SATMED-Q is that the
primary validation enrolled patient samples obtained
in Spain; consequently, validation of this instrument in
international settings is unknown and must be tested.
Conclusions
The SATMED-Q questionnaire is a recently developed
patient-reported outcomes generic measure to assess
treatment satisfaction. The ﬁndings of the present study
suggest that the instrument has good acceptability as
well as satisfactory psychometric properties, including
validity of the subscales and reliability of the subscales
and composite scales. The ﬁndings support the use of
the SATMED-Q as a treatment satisfaction with medi-
cation measure both in daily medical practice and in
clinical research. Moreover, the SATMED-Q instru-
ment may contribute to our understanding of patient
medication-related decisions and behaviors, thus
proving SATMED-Q to be both an important determi-
nant and outcome of effective clinical care.
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